| Literature DB >> 22789414 |
Michael Landgrebe1, Andréia Azevedo, David Baguley, Carol Bauer, Anthony Cacace, Claudia Coelho, John Dornhoffer, Ricardo Figueiredo, Herta Flor, Goeran Hajak, Paul van de Heyning, Wolfgang Hiller, Eman Khedr, Tobias Kleinjung, Michael Koller, Jose Miguel Lainez, Alain Londero, William H Martin, Mark Mennemeier, Jay Piccirillo, Dirk De Ridder, Rainer Rupprecht, Grant Searchfield, Sven Vanneste, Florian Zeman, Berthold Langguth.
Abstract
Chronic tinnitus is a common condition with a high burden of disease. While many different treatments are used in clinical practice, the evidence for the efficacy of these treatments is low and the variance of treatment response between individuals is high. This is most likely due to the great heterogeneity of tinnitus with respect to clinical features as well as underlying pathophysiological mechanisms. There is a clear need to find effective treatment options in tinnitus, however, clinical trials differ substantially with respect to methodological quality and design. Consequently, the conclusions that can be derived from these studies are limited and jeopardize comparison between studies. Here, we discuss our view of the most important aspects of trial design in clinical studies in tinnitus and make suggestions for an international methodological standard in tinnitus trials. We hope that the proposed methodological standard will stimulate scientific discussion and will help to improve the quality of trials in tinnitus.Entities:
Mesh：
Year: 2012 PMID： 22789414 PMCID： PMC3897200 DOI： 10.1016/j.jpsychores.2012.05.002
Source DB: PubMed Journal: J Psychosom Res ISSN： 0022-3999 Impact factor: 3.006